ANI
03 Apr 2026, 14:30 GMT+10
By Nikhil Dedha
New Delhi [India], April 3 (ANI): The recent decision by US President Donald Trump to impose a 100 per cent tariff on patented pharmaceutical imports to US is unlikely to cause immediate disruption to Indian drugmakers, as the move largely targets branded medicines while exempting generics and biosimilars, said Siddharth Mittal, CEO and Managing Director of Biocon Limited.
In an exclusive interaction with ANI, Mittal said the tariff action is aimed at boosting domestic manufacturing in the United States but does not significantly impact Indian players in the near term.
'The recent tariff action by President Trump is clearly aimed at incentivising domestic manufacturing in the US. However, the current framework is targeted at branded and patented drugs, with generics and biosimilars largely exempt, which limits any immediate disruption for Indian players like Biocon,' he said.
Mittal added that the exclusion of generics provides a cushion for India's pharmaceutical exports, particularly to the US, where Indian companies have a strong presence.
'In the near term, the exclusion of generics offers a buffer, ensuring continuity in exports of low-cost medicines that form the backbone of India's pharmaceutical trade with the US,' he said, noting that Indian drugmakers command a significant share in the US generics market.
However, he cautioned that the move signals rising protectionism in global trade, which could impact the industry in the longer term.
'That said, the move does introduce a layer of policy uncertainty. While the direct impact is contained for now, the broader signal is one of increasing protectionism, which industry will be closely watching,' Mittal said.
The United States has recently announced sweeping trade measures targeting patented pharmaceutical imports and metals, with a 100 per cent tariff applicable to patented drug imports from countries, including India.
Mittal also highlighted that the pharmaceutical sector continues to face challenges from rising logistics and supply chain costs amid ongoing geopolitical tensions.
'We have seen a rise in logistics and supply chain costs due to disruptions in key shipping routes. Insurance costs have also risen, and longer transit times are becoming the norm,' he said.
He further pointed out that the ongoing conflict in West Asia remains a key concern for the industry, even though pharmaceuticals are considered an essential sector.
'While pharmaceuticals are relatively resilient, any prolonged instability in the region impacts energy prices, shipping routes, and overall trade flows, which in turn affects input costs and delivery timelines,' he added.
Sharing the outlook for the upcoming financial year, Mittal said, 'Looking ahead to FY27, we remain cautiously optimistic. Demand fundamentals for pharmaceuticals--especially generics, biosimilars, and speciality therapies--remain strong globally,' he said.
He added that India will continue to play a critical role in supplying cost-effective medicines worldwide, though future growth will depend on evolving global trade policies and the industry's ability to manage cost pressures and diversify supply chains. (ANI)
Get a daily dose of Baton Rouge Post news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Baton Rouge Post.
More InformationBEIJING, China: Chinese chipmakers are rapidly gaining ground in the country's artificial intelligence hardware market, capturing a...
NEW YORK, New York - Global stock markets delivered a deeply uneven performance on Thursday, with investors showing little of the usual...
BOLOGNA, Italy: The Iran war is rippling through the global beauty industry, pushing up costs for everything from packaging materials...
WASHINGTON, D.C.: Eli Lilly has secured U.S. approval for its weight-loss pill, marking a major step into the growing obesity treatment...
CAPE CANAVERAL, Florida: Elon Musk's SpaceX has confidentially filed for a U.S. initial public offering, according to two people familiar...
DUBLIN, Ireland: The Government is doing a balancing act with fuel prices even as it prepares for the worst, said Tánaiste Simon Harris...
BOLOGNA, Italy: The Iran war is rippling through the global beauty industry, pushing up costs for everything from packaging materials...
Chandigarh (Punjab) [India], April 3 (ANI): Congress Member of Parliament Manish Tewari on Friday demanded that the central government...
By Nikhil Dedha New Delhi [India], April 3 (ANI): The recent decision by US President Donald Trump to impose a 100 per cent tariff...
US intelligence findings are said to differ from official claims about Operation Epic Furys effectiveness Around half of Iran's missile...
Gen. Randy George was dismissed after he clashed with the US secretary of war over promotions for black and female army officers, the...
Moscow and New Delhi are looking to step up trade in energy and fertilizers amid the Middle East crisis Russian Deputy Prime Minister...
